A number of other research firms have also recently commented on CBMG. BidaskClub upgraded shares of Cellular Biomedicine Group from a hold rating to a buy rating in a report on Wednesday, January 10th. Maxim Group cut shares of Cellular Biomedicine Group from a buy rating to a hold rating in a report on Thursday, February 1st.
Shares of Cellular Biomedicine Group stock opened at $19.90 on Friday. Cellular Biomedicine Group has a fifty-two week low of $5.05 and a fifty-two week high of $22.75. The firm has a market cap of $338.38, a PE ratio of -11.24 and a beta of 3.71.
Cellular Biomedicine Group (NASDAQ:CBMG) last posted its quarterly earnings results on Tuesday, March 6th. The biotechnology company reported ($0.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.08). Cellular Biomedicine Group had a negative net margin of 7,564.10% and a negative return on equity of 45.60%. The firm had revenue of $0.07 million for the quarter. analysts forecast that Cellular Biomedicine Group will post -1.94 earnings per share for the current fiscal year.
In related news, CEO Tony Liu bought 29,167 shares of the company’s stock in a transaction that occurred on Friday, December 22nd. The shares were bought at an average price of $12.00 per share, for a total transaction of $350,004.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Yihong Yao bought 4,167 shares of the company’s stock in a transaction that occurred on Friday, December 22nd. The stock was bought at an average price of $12.00 per share, for a total transaction of $50,004.00. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 41,667 shares of company stock worth $500,004. Corporate insiders own 8.20% of the company’s stock.
An institutional investor recently bought a new position in Cellular Biomedicine Group stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Cellular Biomedicine Group Inc (NASDAQ:CBMG) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 10,041 shares of the biotechnology company’s stock, valued at approximately $107,000. Zurcher Kantonalbank Zurich Cantonalbank owned about 0.07% of Cellular Biomedicine Group at the end of the most recent quarter. 2.79% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This article was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.thelincolnianonline.com/2018/03/19/cellular-biomedicine-group-cbmg-earns-buy-rating-from-b-riley.html.
Cellular Biomedicine Group Company Profile
Cellular Biomedicine Group Inc is a United States-based company which is engaged in the development of cell therapy technologies. The Company develops proprietary cell therapies for the treatment of cancer and degenerative diseases. The Company conducts immuno-oncology and stem cell clinical trials in China using products from the good manufacturing practices (GMP) laboratory.
Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.